Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 5/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17334270 | 1.00 | SYK (0.41) | SYKGRM5CHRM3PCSK9CPB2 | |
| SCHEMBL17340791 | 0.89 | SYK (0.44) | SYKGRM5PCSK9 | |
| SCHEMBL25428186 | 0.82 | PCSK9 (0.38) | SYKPCSK9CPB2GFERHSD17B10 | |
| SCHEMBL25428181 | 0.82 | PCSK9 (0.38) | SYKPCSK9CPB2GFERHSD17B10 | |
| SCHEMBL13836586 | 0.81 | GRM5 (0.39) | SYKGRM5PCSK9KDM4AGFER | |
| SCHEMBL26025544 | 0.80 | SERPINE1 (0.37) | SYKPCSK9CPB2GFERHSD17B10 | |
| SCHEMBL30519641 | 0.79 | AAK1 (0.39) | SYKPCSK9CPB2GFERHSD17B10 | |
| SCHEMBL16270170 | 0.77 | SYK (0.52) | SYKL3MBTL1 | |
| SCHEMBL9900973 | 0.76 | GRM5 (0.41) | GRM5 | |
| SCHEMBL25272136 | 0.76 | HDAC6 (0.46) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676782-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | GRM3, GRM1, GRIN3A | SYK 2968/4885GRM5 8/4885CHRM3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.